Carboxylesterase 2 is downregulated in colorectal cancer following progression of the disease

Cancer Invest. 2008 Mar;26(2):178-81. doi: 10.1080/07357900701560786.

Abstract

Expression of carboxylesterase 2 in colorectal tumor tissues and serum carboxylesterase 2 levels at different stages of the disease were investigated by Western blotting. Carboxylesterase 2 was decreasing in tumor tissues from TNM stages 0 through IV (n = 20); the expression of carboxylesterase 2 was similar between "normal" and tumor tissues (n = 20); serum carboxylesterase 2 levels were similar among patients at different stages of the disease. These results indicate that local expression of carboxylesterase 2 is downregulated following progression of the disease; carboxylesterase 2 expression is altered in histology "normal" tissues from stages I through IV before histopathological changes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / enzymology*
  • Adenocarcinoma / pathology
  • Animals
  • Antineoplastic Agents, Phytogenic / therapeutic use
  • Biomarkers, Tumor / metabolism*
  • Blotting, Western
  • Camptothecin / analogs & derivatives
  • Camptothecin / therapeutic use
  • Carboxylesterase / metabolism*
  • Colorectal Neoplasms / drug therapy
  • Colorectal Neoplasms / enzymology*
  • Colorectal Neoplasms / pathology
  • Disease Progression
  • Down-Regulation
  • Humans
  • Immunoglobulin G / immunology
  • Irinotecan
  • Mice
  • Neoplasm Staging
  • Topoisomerase I Inhibitors

Substances

  • Antineoplastic Agents, Phytogenic
  • Biomarkers, Tumor
  • Immunoglobulin G
  • Topoisomerase I Inhibitors
  • Irinotecan
  • CES2 protein, human
  • Carboxylesterase
  • Camptothecin